Sex-Specific Effects of Endocrine Disruption on Aging and Alzheimer's Disease
Phase 4
Active, not recruiting
- Conditions
- Alzheimer Disease
- Interventions
- Drug: 18-F-Flortaucipir
- Registration Number
- NCT03821857
- Lead Sponsor
- Mayo Clinic
- Brief Summary
The researchers are trying to determine whether ovarian hormones are associated with aging processes and with the risk of developing Alzheimer's disease in women.
- Detailed Description
The proposed project will enroll 200 women. Each women will have one clinic visit consisting of cognitive testing, tests of physical function, questionnaires, and a blood draw. All women will also undergo clinical neuroimaging, which includes structural MRI, β-amyloid (Aβ) deposition on PET as a biomarker of Aβ pathology, and tau deposition on PET as a marker of neurofibrillary tangles using AV-1451.
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- Female
- Target Recruitment
- 200
Inclusion Criteria
- Women who lived in Olmsted County, Minnesota between 1988 and 2007
- Currently aged 55 years and older
- More than six months post chemotherapy or major surgery requiring general anesthesia
- Willing and able to sign informed consent
Exclusion Criteria
- Not able to read and speak English
- In hospice
- Claustrophobic
- If undergoing Tau imaging, cannot have QT Prolongation
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Women 18-F-Flortaucipir 18F-Flortaucipir and 11C-Pittsburgh compound-B radioligands will be used for experimental PET imaging of beta-amyloid and neurofibrillary tau pathology
- Primary Outcome Measures
Name Time Method 18F-Flortaucipir PET imaging 1 day Cortical 18F-Flortaucipir PET imaging measured once in each participant
Pittsburgh compound-B PET imaging 1 day Global cortical SUVR measured once in each participant
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Mayo Clinic
🇺🇸Rochester, Minnesota, United States